期刊
AMERICAN JOURNAL OF THE MEDICAL SCIENCES
卷 345, 期 6, 页码 497-500出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MAJ.0b013e31827ad893
关键词
Aldosterone; Peroxisome proliferator-activated receptor gamma; Pioglitazone; Primary aldosteronism; Resistant hypertension
资金
- Japan Heart Foundation, Tokyo, Japan
- Japan Vascular Disease Research Foundation, Kyoto, Japan
The peroxisome proliferator-activated receptor gamma (PPAR g) agonists have been reported to have antiproliferative and tumor-suppressive effects. We report a case of 55-year-old man with primary aldosteronism (PA) whose hyperaldosteronism was suppressed with the PPAR gamma agonist pioglitazone. He had drug-resistant hypertension, hypokalemia, and diabetes mellitus. The diagnosis of PA was confirmed by the oral sodium loading test (20.5 mu g/d of urinary aldosterone) and Captopril challenge test (19.5 ng/dL of plasma aldosterone). Computed tomography imaging revealed no apparent adrenal mass. The result of the posture stimulation test was consistent with the diagnosis of idiopathic adrenal hyperplasia. On administration of pioglitazone (30 mg/d) and nifedipine (40 mg/d), hypertension and hypokalemia improved and plasma aldosterone decreased for more than 6 months. The sodium loading test done after 6 months of the administration revealed the near normal results (11.2 ng/dL of plasma aldosterone and 13.1 mu g/d of urinary aldosterone). The findings indicated that pioglitazone suppressed PA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据